Daewoong Pharmaceutical, which had been in charge of the domestic sales and marketing of the original SGLT-2 diabetes drug ‘Forxiga (propanediol hydrate),’ is belatedly entering the generic market through a transfer and acquisition deal.

Daewoong had sold Forxiga until January this year. It is analyzed that Daewoong also entered the generic market after AstraZeneca announced its plan to withdraw the drug from the Korean market in the second half of this year.

According to the industry on the 5th, Daewoong Pharmaceutical will be listing its Forxiga generic ‘Forxilo Tablet 5mg' at a ceiling price of KRW 262 from April through a transfer and acquisition.

Daewoong report